What is in the future for T-cell lymphoma?

Recently, PharmaMar announced the start of a phase 2 clinical trial to evaluate the efficacy of plitidepsin, a potential treatment option for adult patients with relapsed and refractory angioimmunoblastic T-cell lymphoma (AITL).

In this VJHemOnc – Video Journal of Hematological Oncology video, listen to Owen O’Connor, MD, PhD from Columbia University Medical Center, New York talk about the positive trend in the research for treating T-cell lymphoma.

Learn more about the study of cutaneous T-cell lymphoma genomics that is likely to lead to targeted therapies soon.

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Leave a Comment

Your email address will not be published. Required fields are marked *